| Dr Richard Gerrit Bakker, MD PHD | |
|
3555 Olentangy River Rd, Suite 1080, Columbus, OH 43214-3912 | |
| (614) 268-8164 | |
| (614) 268-8406 |
| Full Name | Dr Richard Gerrit Bakker |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 18 Years |
| Location | 3555 Olentangy River Rd, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528244357 | NPI | - | NPPES |
| 2939253 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Mount Carmel St Ann's | Westerville, OH | Hospital |
| Dublin Methodist Hospital | Dublin, OH | Hospital |
| Grady Memorial Hospital | Delaware, OH | Hospital |
| Mount Carmel East & West | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Ohio Primary Care Physicians, Inc. | 2769383785 | 488 |
| Ohiohealth Corporation | 6305758426 | 1900 |
| Mount Carmel Health Providers Two Llc | 6608828447 | 214 |
News Archive
In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Results for the quarter reflect the Company's acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.
› Verified 5 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Results for the quarter reflect the Company's acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.
› Verified 5 days ago
| Entity Name | Central Ohio Primary Care Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194705194 PECOS PAC ID: 2769383785 Enrollment ID: O20040114000204 |
News Archive
In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Results for the quarter reflect the Company's acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.
› Verified 5 days ago
| Entity Name | Mount Carmel Health Providers Two Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134154750 PECOS PAC ID: 6608828447 Enrollment ID: O20050325000023 |
News Archive
In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Results for the quarter reflect the Company's acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Gerrit Bakker, MD PHD 3555 Olentangy River Rd, Suite 1080, Columbus, OH 43214-3912 Ph: (614) 268-8164 | Dr Richard Gerrit Bakker, MD PHD 3555 Olentangy River Rd, Suite 1080, Columbus, OH 43214-3912 Ph: (614) 268-8164 |
News Archive
In a paper published in the premier open-access medical journal PloS Medicine this month, Mukesh Harisinghani and Ralph Weissleder describe a technique that could begin to make the staging of cancer both more accurate and less invasive.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
St. Jude Children's Research Hospital and the University of Florida Proton Therapy Institute have formed a collaboration to provide proton therapy for St. Jude patients. The announcement follows the approval of the first clinical study to evaluate the use of proton therapy for rare brain cancers in children younger than 3 years old.
Results for the quarter reflect the Company's acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.
› Verified 5 days ago
Gerd Mcgwire, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-4950 Fax: 614-722-4966 | |
Dr. Sohaib Abdul Hameed, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 3555 Olentangy River Rd Ste 1080, Columbus, OH 43214 Phone: 614-268-8164 | |
Brett G Nelson, PA Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 3555 Olentangy River Rd Ste 1080, Columbus, OH 43214 Phone: 614-268-8164 Fax: 614-268-8406 | |
Kevin M. Adams, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Max Hugo Saenz, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 111 S Grant Ave, Columbus, OH 43215 Phone: 614-566-8883 | |
Lisa M. Kim, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Rajiv Khush Sheth, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3555 Olentangy River Rd, Suite 1080, Columbus, OH 43214 Phone: 614-268-8164 Fax: 614-268-8406 |